CO5280079A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
CO5280079A1
CO5280079A1 CO00083137A CO00083137A CO5280079A1 CO 5280079 A1 CO5280079 A1 CO 5280079A1 CO 00083137 A CO00083137 A CO 00083137A CO 00083137 A CO00083137 A CO 00083137A CO 5280079 A1 CO5280079 A1 CO 5280079A1
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
independently represent
heteroaryl
aryl
Prior art date
Application number
CO00083137A
Other languages
English (en)
Inventor
David Gurley
James Rosamond
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5280079A1 publication Critical patent/CO5280079A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de la fórmula I <EMI FILE="00083137_1" ID="1" IMF=JPEG >en donde:R1 representa hidrógeno, alquil C1-C4, alquenil C2-C4, alquinil C2-C4, o (CH2)nAr;W representa C(O), C(O)O, C(O)NR6, o un enlace;R2 representa hidrógeno, Ar, o (CH2)pCH[(CH2)qR7](CH2)tR8; o juntos R2 y R6 representan (CH2)jY(CH2)k;R3 y R5 independientemente representan hidrógeno, halógeno, o alquil C1-C4;X representa oxígeno, o NH;R4 representa hidrógeno, alquil C1-C4, (CH2)uAr, R9CO, o R9SO2;R6 representa hidrógeno, alquil C1-C4, aril, o heteroaril; o R2 y R6 juntos representan (CH2)j Y(CH2)k;R7 y R8 independientemente representan hidrógeno, halógeno, CN, -C=CH, N3, CF3, NO2, Ar, OR10, NR10R11, C(O)OR10, OC(O)R10, C(O)NR10R11, NR10C(O)R11, SO2NR10R11, o NR10SO2R11.R9 representa alquil C1-C4, o Ar;Ar representa fenil, naftil, o un anillo heterocíclico de 5- o 6-miembros que contiene 0-3 nitrógenos, 0-1 azufres y 0-1 oxígenos;Ar es opcionalmente substituido con uno o más substituyentes independientemente seleccionados entre: hidrógeno, halógeno, alquil C1-C4, alquenil C2-C4, alquinil C2-C4, (CH2)naril, CN, NO2, CF3 OR12 NR12 R13 y , COOR12;R10, R11, R12 y R13 independientemente representan hidrógeno, alquil C1-C4, aril, o heteroaril; o R10 y R11 juntos y/o R12 y R13 independientemente representan (CH2)jY(CH2)k;Y representa oxígeno, azufre, NR14, o un enlace;j es 2-4;k, m, n, p, q, t, y u son independientemente 0-2;R14 representa hidrógeno, alquil C1-C4, aril o heteroarilo un enantiómero del mismo, y sales farmacéuticamente aceptables del mismo.
CO00083137A 1999-11-03 2000-11-01 Nuevos compuestos CO5280079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903998A SE9903998D0 (sv) 1999-11-03 1999-11-03 New compounds

Publications (1)

Publication Number Publication Date
CO5280079A1 true CO5280079A1 (es) 2003-05-30

Family

ID=20417608

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00083137A CO5280079A1 (es) 1999-11-03 2000-11-01 Nuevos compuestos

Country Status (16)

Country Link
US (2) US7064143B1 (es)
EP (1) EP1230218A1 (es)
JP (1) JP2003513073A (es)
KR (1) KR20020063175A (es)
CN (1) CN1216864C (es)
AU (1) AU783602B2 (es)
BR (1) BR0015193A (es)
CA (1) CA2387741A1 (es)
CO (1) CO5280079A1 (es)
IL (1) IL149096A0 (es)
MX (1) MXPA02004240A (es)
NO (1) NO323077B1 (es)
NZ (1) NZ518449A (es)
SE (1) SE9903998D0 (es)
WO (1) WO2001032622A1 (es)
ZA (1) ZA200203181B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
EP1531820A1 (en) 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
PL380887A1 (pl) 2003-12-29 2007-04-02 Sepracor Inc. Pirolowe i pirazolowe inhibitory DAAO
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
AU2005227324A1 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1756054B1 (en) 2004-06-01 2010-03-31 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20090099176A1 (en) 2004-12-02 2009-04-16 Thomas Martin Krulle Pyrrolopyridine-2-carboxylic acid amides
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
ATE442368T1 (de) 2005-11-30 2009-09-15 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
BRPI0619247A2 (pt) 2005-11-30 2011-09-20 Hoffmann La Roche métodos para a sìntese de 3-amino-1-aril-propila indóis
WO2007062996A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP1944288A1 (en) * 2007-01-09 2008-07-16 Bayer Schering Pharma Aktiengesellschaft Radiolabelling via fluorination of aziridines
KR20090096716A (ko) * 2007-01-09 2009-09-14 바이엘 쉐링 파마 악티엔게젤샤프트 아지리딘의 플루오르화에 의한 방사성표지
GB2448224B (en) * 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758766A (fr) * 1969-11-17 1971-05-10 Ici Ltd Nouveaux derives de la morpholine et de la
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
EP0550507A1 (en) * 1990-09-13 1993-07-14 Beecham Group p.l.c. Indole ureas as 5 ht receptor antagonist
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
WO1993018026A1 (en) 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
US5504101A (en) * 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
FR2722686B1 (fr) * 1994-07-22 1996-08-30 Oreal Set, procede, dispositif et composition de teinture des fibres keratiniques
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
SE9903997D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds

Also Published As

Publication number Publication date
SE9903998D0 (sv) 1999-11-03
US7064143B1 (en) 2006-06-20
JP2003513073A (ja) 2003-04-08
NZ518449A (en) 2004-07-30
MXPA02004240A (es) 2002-10-17
AU783602B2 (en) 2005-11-10
NO20022105D0 (no) 2002-05-02
WO2001032622A1 (en) 2001-05-10
NO20022105L (no) 2002-07-02
KR20020063175A (ko) 2002-08-01
EP1230218A1 (en) 2002-08-14
ZA200203181B (en) 2003-07-22
BR0015193A (pt) 2002-06-18
CN1216864C (zh) 2005-08-31
CN1387513A (zh) 2002-12-25
AU1426301A (en) 2001-05-14
IL149096A0 (en) 2002-11-10
CA2387741A1 (en) 2001-05-10
US7402604B2 (en) 2008-07-22
US20050245595A1 (en) 2005-11-03
NO323077B1 (no) 2006-12-27

Similar Documents

Publication Publication Date Title
CO5280079A1 (es) Nuevos compuestos
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
CO5251458A1 (es) Nuevos compuestos
AR028531A1 (es) Compuestos organicos
CO5261607A1 (es) Nuevo uso
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR025975A1 (es) Compuestos quimicos.
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
PT1140916E (pt) Acetais heteroarilo ciclicos
AR013184A1 (es) Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE231488T1 (de) Harnstoffderivate und ihre anwendung als integrin-inhibitoren
ATE194345T1 (de) Xanthinderivate
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
ATE478885T1 (de) Pharmazeutische dopamin-glykokonjugat- zusammensetzungen und verfahren zu deren herstellung
AR008296A1 (es) Compuestos derivados de tetrahidroquinolina, proceso para su preparacion, composiciones que los contienen y su uso en la preparacion de una composicion
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
HUP9802143A2 (hu) 5-Tagú heterociklusos vegyületek, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
HUP9801382A2 (hu) Neurokinin antagonista piperazinszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
DK304289A (da) Benzenderivater
CO5160261A1 (es) Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
CO5221057A1 (es) Componentes y composiciones plagicidas
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden

Legal Events

Date Code Title Description
FA Application withdrawn